SAN Sanofi

Sanofi: Information concerning the total number of voting rights and shares - September 2020

Sanofi: Information concerning the total number of voting rights and shares - September 2020

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority)

Sanofi

a French société anonyme with a registered share capital of 2,517,873,886 €

Registered office : 54, rue La Boétie – 75008 Paris – France

Registered at the Paris Commercial and Companies Registry under number 395 030 844

Date  



Total number of

issued shares



  		Number of real

voting rights

(excluding treasury shares) 		Theoretical number of

voting rights

(including treasury shares)*
September 30, 2020 1,258,964,700 1,411,103,526 1,413,699,285

*  Pursuant to article 223-11 of the Règlement général de l’Autorité des Marchés Financiers.

This information is also available on the internet website of sanofi under « Regulated Information in France »:

Investor Relations Department

Europe Tel: 45           US Tel: 0

e-mail:



 



Media Relations Department

Tel: 46

 e-mail:



 

 

Attachment

EN
27/10/2020

Underlying

SANSanofi

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sanofi

Martial Descoutures
  • Martial Descoutures
10h / 25m 10h / 25m 1 EN
Martial Descoutures
  • Martial Descoutures
10h / 31m 10h / 31m 1 FR
Research Department
  • Research Department
SAN SANOFI
IBE IBERDROLA SA
VOW VOLKSWAGEN (VOW GR)
12h / 42m 12h / 42m 1 ES
 PRESS RELEASE
Free
SAN SANOFI

Press Release: Update on the US regulatory review of tolebrutinib in n...

Press Release: Update on the US regulatory review of tolebrutinib in non-relapsing, secondary progressive multiple sclerosis Update on the US regulatory review of tolebrutinib in non-relapsing, secondary progressive multiple sclerosis Paris, September 22, 2025. The US Food and Drug Administration (FDA) has extended by three months the target action date of its review of the new drug application (NDA) of tolebrutinib, an oral and brain-penetrant investigational Bruton's tyrosine kinase (BTK) inhibitor to treat non-relapsing, secondary progressive multiple sclerosis (nrSPMS) and to slow di...

14h / 1m 1 EN
 PRESS RELEASE
Free
SAN SANOFI

Communiqué de presse : Mise à jour sur l’examen réglementaire américai...

Communiqué de presse : Mise à jour sur l’examen réglementaire américain du tolébrutinib dans le traitement de la sclérose en plaques secondairement progressive non récurrente Mise à jour sur l’examen réglementaire américain du tolébrutinib dans le traitement de la sclérose en plaques secondairement progressive non récurrente Paris, le 22 septembre 2025. La Food and Drug Administration (FDA) des États-Unis a prolongé de trois mois la date limite d’action de son examen de la demande de nouveau médicament (New Drug Application, NDA) du tolébrutinib, un inhibiteur de la tyrosine kinase de Br...

14h / 1m 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch